Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Facilitating an open dialogue with patients, to better understand their needs, makes research efforts more valuable in the long-term
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target
Continued collaboration to identify new molecular targets and treatments can build on existing success
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.